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DOI: 10.1039/c2an35298bA methodology based on micellar liquid chromatography to monitor five antiretroviral drugs
(lamivudine, stavudine, tenofovir, zidovudine and efavirenz) was proposed. Antiretrovirals were
studied in sets of three, corresponding to each highly active antiretroviral therapy (HAART) regime,
prescribed to acquired immunodeficiency syndrome (AIDS)-infected patients. Four aqueous micellar
mobile phases buffered at pH 7 were optimized to separate these compounds, using sodium dodecyl
sulfate as the tensioactive, and 1-propanol or 1-pentanol as the organic modifier. The composition of
each mobile phase was optimized for each antiretroviral. The common separation conditions were: C18
apolar column (125  4.6 mm, 5 mm particle size), UV detection set at 214 nm, and mobile phase
running at 1 mL min1 without controlling the temperature. The finally suggested method was
validated for five analysed antiretroviral drugs following the US Food and Drug Administration
guidelines in terms of: linearity between 0.5 and 50 ppm (r2 > 0.9995), sensitivity (LOD lower than 0.25
ppm), intra- and inter-day precision (<7.1 and <5.2%, respectively) and accuracy (recovery 88.5–
105.3% and 93.5–101.3%, respectively), as well as robustness (<6.5%). The proposed method was used
to monitor the level of antiretrovirals in the serum of AIDS patients. The suggested methodology was
found to be useful in the routine analysis of antiretrovirals in serum samples.1. Introduction
Acquired immunodeficiency syndrome (AIDS) is a disease
provoked by the human immunodeficiency virus 1 (HIV-1),
which strongly affects the human immunological system.1
Currently, HIV/AIDS is the fourth greatest cause of death
worldwide. It is estimated that 40 million people are infected with
HIV and 22 million have died of the disease.2 HIV-1 is spread
between by blood contact and sexual relationships3 and through
blood, amniotic fluid and/or breast milk from a mother to her
child.4 A definitive cure has not been found, but in 1996, the
highly active antiretroviral therapy (HAART) was proposed,
with impressive clinical results in suppressing the activity of
HIV.5 HAART involves different kinds of antiretroviral drugs,
such as: nucleoside reverse transcriptase inhibitors (NRTIs):
abacavir, didanosine, emtricitabine, lamivudine, stavudine,
tenofovir, zalcitabine and zidovudine; non-nucleoside reverse
transcriptase inhibitors (NNRTIs): delavirdine, nevirapine and
efavirenz; and protease inhibitors (PIs): amprenavir, atazanavir,
darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, rito-
navir, saquinavir and tipranavir.6,7aDep. de Farmacia Hospitalaria, Hospital la Plana, 12540 Vila-real, Spain
bDep. de Quımica Fısica i Analıtica, E.S.T.C.E., Universitat Jaume I,
Campus Riu Sec, 12071 Castello, Spain. E-mail: vicentej@qfa.uji.es;
Fax: +34 964728066; Tel: +34 964728099
This journal is ª The Royal Society of Chemistry 2012HAART regimes contain three or four drugs, two NRTIs and
one or two NNRTIs, or one or two PIs. The hydrophobicity is
assessed by the quotient of the solubility in octanol and in water
(Po/w). A high value of Po/w indicates a high hydrophobicity.
8
The mixtures more administrated are: (a) lamivudine (log
Po/w ¼ 1.4), zidovudine (log Po/w ¼ 0.05) and efavirenz (log
Po/w ¼ 4.46); (b) lamivudine, stavudine (log Po/w ¼ 0.8) and
efavirenz; and (c) lamivudine, tenofovir (log Po/w ¼ 1.6) and
efavirenz. For each patient, one HAART set of antiretrovirals is
prescribed.6,9
Therapeutic drug monitoring (TDM) consists of the determi-
nation of the amount of a drug in the blood. This information
can be used by the clinician to establish many aspects of patient
treatment, such as malabsorption, drug interactions, individual
drug pharmacokinetics and the way each person metabolizes the
drug.10 This can explain the different effects of the drug
depending on the patient and the possible secondary effects. On
the other hand, the presence of sub-therapeutic levels of anti-
retroviral drugs in the blood may provoke the virus to develop
resistance.11 This can help to determine the proper dose to be
taken for a particular person.6 However, as each patient takes
only one of the HAART regimes, the screening of a wide amount
of antiretrovirals is large. Clinics need analytical methods to
quantify the three antiretrovirals belonging to the corresponding
HAART. The be able to optimize the methodology for a low
number of analytes instead of a high number will allow theAnalyst, 2012, 137, 4327–4334 | 4327
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View Article Onlinedevelopment of a methodology with a lower analysis time and
more selectivity, sensitivity and resolution.12
We have previously developed a methodology based on
micellar liquid chromatography for the screening of 13 anti-
retroviral drugs by the use of only three mobile phases.6 The use
of micellar solvents is especially useful in samples with serum
matrices, because serum contains hydrophobic compounds
which are harmful for the chromatographic system.13–15 Micellar
media denaturalize and solubilize hydrophobic substances,
releasing possible interferent-analyte adducts and avoiding
precipitation into the columns.8,16 After a simple dilution and
filtration, samples are able to be directly injected, expediting the
experimental procedure.17 Our previously developed analytical
method6 can be adapted by the modification of the mobile phases
in order to analyze three determined antiretrovirals. This way,
this modified methodology will keep the benefits of micellar
liquid chromatography, including the use of a low amount of
pollutant chemicals.18
The aim of this work is to develop an analytical methodology
to determine each of the most used sets of three antiretroviral
drugs used in HAART in serum. The selected HAART sets of
antiretrovirals were: lamivudine + zidovudine + efavirenz, lam-
ivudine + stavudine + efavirenz and lamivudine + tenofovir +
efavirenz. The methodology must be validated in terms of linear
interval, sensitivity, selectivity, limits of detection and quantifi-
cation, precision, accuracy and robustness, following the guide-
lines of the FDA.19 The developed analytical method was used to
quantify the analytes in human serum from AIDS patients.
2. Experimental procedure
2.1 Chemicals and reagents
Sodium dodecyl sulphate (SDS, 99% purity) was obtained from
Merck (Darmstadt, Germany). Sodium dihydrogen phosphate
monohydrate and HCl were ordered from Panreac (Barcelona,
Spain). NaOH came from Scharlab (Barcelona, Spain). Meth-
anol was bought from J.T. Baker (Deventeer, The Netherlands)
and 1-propanol and 1-pentanol came from Scharlab. An ultra-
pure water device (Millipore S.A.S., Molsheim, France) was used
to prepare the aqueous solutions and mobile phases.
The antiretrovirals studied were: efavirenz (E), lamivudine (L),
zidovudine (Z) (purity >99.9%, Filaxis, Cordoba, Argentina),
tenofovir (T), stavudine (S) (purity >99.9% Bristol Myers
Squibb, New York, NY, USA). The antiretrovirals were studied
grouped in sets as follows: mixture 1 ¼ L + Z + E; mixture 2 ¼
L + S + E; and mixture 3 ¼ L + T + E.
2.2. Equipment and chromatographic conditions
A Metter-Toledo analytical balance (Greifensee, Switzerland)
was used to weigh the analyte. The pH was measured with a
Crison potentiometer (Barcelona, Spain) equipped with a
combined Ag/AgCl/glass electrode. An ultrasonic bath was used
to dissolve the standards (model Ultrasons-H, Selecta, Abrera,
Spain).
Chromatographic separations were performed using an Agi-
lent Technologies Series 1100 system (Palo Alto, CA, USA)
equipped with an isocratic pump, a degasser, an autosampler and
an absorbance diode array detector (DAD). The stationary4328 | Analyst, 2012, 137, 4327–4334phase was in a Kromasil C18 column with the following char-
acteristics: pore size 100 A, length 15 cm, internal diameter
4.6 mm, particle size 5 mm. Several mobile phases were tested by
varying the SDS concentration, the amount of 1-propanol and
1-pentanol, and the pH. The optimal mobile phase composition
for each antiretroviral and its corresponding retention time are
shown in Table 1. In all cases, the pH was fixed to 7 using 0.01 M
disodium monohydrogen phosphate buffer. Mobile phases run
under the isocratic mode at 1 mL min1 without controlling the
temperature. The injection volume was 20 mL and detection was
set at 214 nm. The solutions and the mobile phases were filtered
through 0.45 mm nylon membranes (Micron Separations, West-
boro, MA, USA). Special care was taken for the chromato-
graphic system, due to the use of micellar solutions.8
2.3 Blood collection
The blood samples used for spiking were taken from healthy,
AIDS-infected and heroin addict AIDS-infected volunteers.
These samples were collected with DB SST Tubes (BD Vacu-
tainer Systems, Plymouth, UK), centrifuged at 3000 rpm for 10
min and serum was finally separated and either used immediately
or frozen and stored at 20 C. Blood samples were provided by
the La Plana Hospital in Vilarreal and the General Hospital in
Castello, Spain, after consent had been obtained from the Ethical
Committee and from patients.
2.4. Solution and sample preparation
Mobile phases were prepared by dissolving the appropriate
amount of SDS and disodium monohydrogen phosphate in
ultrapure water. Then the pH was adjusted by adding drops of
HCl or NaOH solutions to reach the desired value. Furthermore,
the appropriate volume of organic solvent (1-propanol or 1-
pentanol) was added and the solution was adjusted to the desired
volume with ultrapure water, ultrasonicated and filtered.
Stock solutions of each antiretroviral were prepared in meth-
anol–water 5 : 95 (v/v). Working solutions were prepared by
diluting these stock solutions in ultrapure water. All stock and
working solutions stored at +4 C were stable for at least 3
months.6
For optimization and validation studies, spiked serum samples
were prepared by adding the appropriate volume of stock or
working solution to 0.5 mL of serum and then adjusting the final
volume to 5 mL with a 0.05 M SDS aqueous solution buffered at
pH 7. The sample was vigorously shaken to favor homogeniza-
tion and stored for one day in the fridge at 5 C to favor the
contact between analytes and the sample, and also solvent
evaporation.20,21 Then the serum was 1/10 diluted.
2.5 Statistical treatment of the data
In order to perform the optimization, the selected chromato-
graphic parameters were studied: retention time (tR: time at
maximal value of absorbance signal; min); efficiency (N; number
of theoretical plates); asymmetry (B/A; B ¼ distance between tR
and the time at 0.1  signal height at the end of the peak; A ¼
distance between tR and the time at 0.1  signal height at the
beginning of the peak). These parameters were calculated for
each peak from chromatograms using Michrom software.22This journal is ª The Royal Society of Chemistry 2012
Table 1 Composition of the optimal mobile phase and chromatographic parameters to separate the antiretroviral belonging to each HAART set
Mixture Antiretroviral Retention timea/min SDS amount/M
Organic modifier
(concentration, %)
Efficiency
(N)
Asymmetry
(B/A)
1 Lamivudine 2.05  0.06
0.05 1-propanol (2.5%)
2046 1.286
Zidovudine 2.58  0.05 2694 1.178
Efavirenz 14.20  0.15 0.05 1-pentanol (6%) 2569 1.062
2 Stavudine 2.65  0.07
0.05 —
2462 1.202
Lamivudine 4.96  0.09 2172 1.287
Efavirenz 14.20  0.15 0.05 1-pentanol (6%) 2569 1.062
3 Lamivudine 2.69  0.05 0.15 — 2009 1.103
Tenofovir 4.01  0.04
0.05 1-pentanol (6%)
2060 1.172
Efavirenz 14.20  0.15 2569 1.062
a n ¼ 5.
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View Article OnlineA chromatographic peak is considered satisfactory if the
retention time is low, but higher than 2 min (far enough from
dead time), the efficiency is high and the asymmetry is close to 1.
Optimization was made by the criterion of obtaining more
satisfactory chromatographic peaks (see above) without
overlapping.8Fig. 1 Chromatograms obtained by analysis of antiretroviral standard (20 pp
propanol for lamivudine and zidovudine in mixture 1; (B) 0.05M SDS/6% 1-pe
M SDS for stavudine and lamivudine in mixture 2, and (D) 0.15 M SDS for
This journal is ª The Royal Society of Chemistry 20123. Results and discussion
3.1 Optimization of the separation conditions
The separation conditions were changed from those proposed in
ref. 6 in order to improve the chromatographic parameters
(efficiency, asymmetry and retention time) by focusing the study
in the three compounds of each HAART mixture potentiallym) using for each one its optimized mobile phase: (A) 0.05M SDS/2.5% 1-
ntanol for tenofovir (in mixture 3) and efavirenz (in all mixtures); (C) 0.05
lamivudine in mixture 3.
Analyst, 2012, 137, 4327–4334 | 4329
Table 2 Regression curves parameters (slope, intercept and regression
coefficient) and sensitivity values (LOD and LOQ) calculated for each
studied antiretroviral
Mixture Compound Slope Intercept r2 LOD/ppm
1 Lamivudine 37.5  0.2 5.1  1.9 0.9999 0.18
1 Zidovudine 43.5  0.3 5  8 0.9998 0.15
1/2/3 Efavirenz 58.3  0.4 3  4 0.9997 0.10
2 Stavudine 52.7  0.3 5  9 0.9995 0.15
2 Lamivudine 35.7  0.3 4  2 0.9999 0.21
3 Lamivudine 36.5  0.2 4  3 0.9996 0.20
3 Tenofovir 44.8  0.3 2  3 0.9997 0.25
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View Article Onlineadministrated to a patient, instead of a wide number of inde-
pendent antiretrovirals. The study was limited to isocratic-
running mobile phases, because no stabilization time is required
between two injections, increasing the robustness and the
number of analyzed samples per day. The optimization was
performed using standards 1/10-diluted in 0.05 M SDS at pH 7.
The stationary phase, pH of the mobile phase and the detec-
tion wavelength were set as C18, 7 and 214 nm, respectively,
because it was proven in ref. 6 that these conditions provide an
adequate separation and sensitivity. Moreover, the selected pH is
inside the working pH of the column (1.5–9.5). The improvement
of the chromatographic parameters was made by varying the
mobile phase composition (SDS and organic modifier amount).Table 3 Intra- and inter-day precision and accuracy for the detection of each
methodology
Mixture Antiretroviral Spiked concentration/ppm
1 Lamivudine 0.5
5.0
20
1 Zidovudine 0.5
5.0
20
1/2/3 Efavirenz 0.5
5.0
20
2 Stavudine 0.5
5.0
20
2 Lamivudine 0.5
5.0
20
3 Lamivudine 0.5
5.0
20
3 Tenofovir 0.5
5.0
20
a n ¼ 6. b n ¼ 5.
4330 | Analyst, 2012, 137, 4327–4334Lamivudine, zidovudine, stavudine and tenofovir are quite
polar compounds, according to their low log Po/w. That means
that using a C18 column and pure mobile phase would provide
adequate resolution and retention time. However, a short chain
alcohol (as 1-propanol) can be added in order to improve the
chromatographic parameters. On the other hand, efavirenz has a
high log Po/w, indicating that it is more hydrophobic, and would
show a high retention time. In this case, an organic modifier
(1-butanol or 1-pentanol) should be added to the SDS aqueous
mobile phase to obtain useful chromatographic parameters.
Then optimization of mobile phases was performed by testing a
pure SDS aqueous mobile phase and adding 1-propanol,
1-butanol and 1-pentanol.
In order to find the most adequate mobile phase composition,
each antiretroviral (20 ppm standard) was analyzed the following
mobile phases, containing SDS mM/modifier %: 0.05/0; 0.10/0;
0.15/0; 0.05/1-propanol 2.5; 0.05/1-propanol 12.5; 0.1/1-propanol
7.5; 0.15/1-propanol 2.5; 0.15/1-propanol 12.5; 0.05/1-butanol 1;
0.05/1-butanol 7; 0.1/1-butanol 4; 0.15/1-butanol 1; 0.15/1-
butanol 7; 0.05/1-pentanol 2; 0.05/1-pentanol 6; 0.1/1-pentanol 4;
0.15/1-pentanol 2 and 0.15/1-pentanol 6. The obtained chro-
matographic peaks were used for optimization as indicated in
Section 2.5.
The optimized mobile phases are indicated in Table 1, and
the chromatograms obtained by the analysis of the standards
under the selected chromatographic conditions are shown
in Fig. 1.studied antiretroviral and HAART set obtained by applying the analytical
Intradaya Interdayb
Accuracy
(%) Precision (%)
Accuracy
(%)
Precision
(%)
105.3 4.4 99.1 2.9
102.3 3.3 101.2 3.0
95.5 2.5 99.8 1.5
89.8 5.2 95.2 4.0
95.5 4.8 94.7 3.5
99.1 1.1 97.0 3.0
92.1 6.1 97.5 4.2
98.5 5.2 95.5 1.8
99.8 4.8 97.5 2.2
89.5 6.2 96.5 5.2
92.5 4.2 98.5 3.5
98.2 3.1 97.5 2.4
103.3 4.9 97.1 1.9
101.3 1.7 98.2 2.0
97.5 3.5 99.8 0.9
102.5 3.5 98.5 3.8
101.3 1.9 99.5 0.5
98.5 2.5 97.5 1.2
88.5 7.1 93.5 4.2
92.5 4.2 95.6 2.8
98.5 2.8 99.6 1.2
This journal is ª The Royal Society of Chemistry 2012
Table 4 Evaluation of the robustness of the micellar liquid chromatography methoda
Mixture Antiretroviral Parameter Level Retention time/min (RSD, %) Area (arbitrary unit) (RSD, %)
1 Lamivudine Conc. SDS/mol L1 0.45–0.55 2.11  0.10 (4.7) 778  23 (3.0)
pH 6.9–7.1 2.06  0.09 (4.4) 762  25 (3.3)
1-Propanol (%) 1.9–2.1 2.04  0.11 (5.4) 758  30 (4.0)
Flow/mL min1 0.95–1.05 2.05  0.13 (6.3) 750  17 (2.3)
1 Zidovudine Conc. SDS/mol L1 0.45–0.55 2.60  0.09 (3.5) 870  19 (2.2)
pH 6.9–7.1 2.55  0.11 (4.3) 861  21 (2.4)
1-Propanol (%) 1.9–2.1 2.61  0.12 (4.6) 880  30 (3.4)
Flow/mL min1 0.95–1.05 2.52  0.10 (4.0) 851  14 (1.6)
1/2/3 Efavirenz Conc. SDS/mol L1 0.45–0.55 14.4  0.5 (3.5) 1200  50 (4.2)
pH 6.9–7.1 14.1  0.4 (2.8) 1130  30 (2.7)
1-Pentanol 5.9–6.1 14.5  0.5 (3.4) 1150  40 (3.5)
Flow/mL min1 0.95–1.05 14.2  0.6 (4.2) 1190  30 (2.5)
2 Stavudine Conc. SDS/mol L1 0.45–0.55 2.60  0.17 (6.5) 1070  40 (3.7)
pH 6.9–7.1 2.68  0.1 (4.1) 1050  20 (1.9)
Flow/mL min1 0.95–1.05 2.62  0.23 (5.0) 1030  30 (2.9)
2 Lamivudine Conc. SDS/mol L1 0.45–0.55 5.01  0.22 (4.4) 724  24 (3.3)
pH 6.9–7.1 4.92  0.15 (3.0) 720  15 (2.1)
Flow/mL min1 0.95–1.05 4.98  0.19 (3.8) 710  20 (2.8)
3 Lamivudine Conc. SDS/mol L1 0.145–0.155 2.72  0.11 (4.0) 750  24 (3.2)
pH 6.9–7.1 2.67  0.08 (3.0) 731  19 (2.6)
Flow/mL min1 0.95–1.05 2.70  0.09 (3.3) 742  16 (2.2)
3 Tenofovir Conc. SDS/mol L1 0.45–0.55 4.06  0.13 (3.2) 870  30 (3.4)
pH 6.9–7.1 4.04  0.09 (2.2) 910  19 (2.1)
1-Pentanol 5.9–6.1 3.95  0.13 (3.0) 890  24 (2.7)
Flow/mL min1 0.95–1.05 4.00  0.17 (4.3) 900  15 (1.7)
a n ¼ 6.
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View Article Online3.1.1 Separation conditions for lamivudine and efavirenz. As
these two compounds are in the three mixtures, and their results
are firstly discussed.
Lamivudine shows a low retention time in all cases (according
to its polarity). Mobile phases providing a retention time lower
than 2.00 min were not considered. In this case, it elutes too close
to the dead time, and the probability of overlapping with matrixFig. 2 Chromatograms obtained by the analysis of a serum sample of the
lamivudine, zidovudine and efavirenz (see Table 5 for quantitative values).
This journal is ª The Royal Society of Chemistry 2012compounds is high. Only a pure aqueous mobile phase, 0.05 M
SDS/1-propanol 2.5% and 0.05 M SDS/1-butanol 1% were able
to elute lamivudine with a retention time of more than 2 min.
Efavirenz provides a high retention time in all cases (in
agreement with its low polarity). Mobile phases eluting the
analyte with a retention time of more than 20 min were not
considered. Indeed, a greater retention time would lower theAIDS patient no. 505459, who takes the HAART regime composed of
Analyst, 2012, 137, 4327–4334 | 4331
Table 5 Amount of antiretroviral found (ppm) in AIDS patient serum
samplesa
HAART regime prescribed ¼ mixture 1
Patient Lamivudine Zidovudine Efavirenz
576704 5.6  0.4 27.7  1.1 125  8
505933 13.7  0.9 36  3 23  3
519824 179.5  1.5 12.8  1.8 Under LOD
521320 5.3  1.5 32.8  0.8 393  9
520287 12  4 29.0  0.3 84  6
516064 7.0  0.9 45.4  1.8 Under LOD
505459 104  8 89  5 122  7
HAART regime prescribed ¼ mixture 2
Patient Lamivudine Stavudine Efavirenz
521787 35  4 130  15 510  40
521321 31  5 72  9 183  22
HAART regime prescribed ¼ mixture 3
Patient Lamivudine Tenofovir Efavirenz
532374 16.6  1.6 Under LOD 91  6
532378 34.3  1.6 Under LOD 305  13
579254 26.7  0.6 Under LOD 1010  50
579253 14.2  0.6 Under LOD 660  40
519821 34.9  1.0 Under LOD 38  4
516060 20.6  2.1 Under LOD 365  21
505948 49  3 Under LOD 150  12
514486 30.7  1.2 Under LOD 24  3
505050 29.3  2.0 Under LOD 13.1  0.4
505045 41.3  1.4 Under LOD 160  7
520289 24  3 Under LOD 159  9
a n ¼ 5.
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View Article Onlineefficiency and is not suitable for routine analysis, where a high
amount of samples should usually be analyzed. Following this
criterion, only 0.15 M/1-propanol 12.5%, 0.15 M/1-butanol 7%,
0.05 M SDS/1-pentanol 6%, 0.1 M SDS/1-pentanol 4% and
0.15 M SDS/1-pentanol 6% were considered.
As seen, the resolution of a mixture of lamivudine and efa-
virenz is not possible in a pure mobile phase, because of the
strong difference of hydrophobicities. Therefore, for each
mixture two mobile phases would be needed. The final selection
of the optimal mobile phase was made separately for each
HAART mixture, depending on the chromatographic parameter
of the third compound (zidovudine, stavudine and tenofovir).
The chromatographic parameters for each analyte in its opti-
mized mobile phase are shown in Table 1.
3.1.2 Mixture 1: lamivudine + zidovudine + efavirenz. In all
tested mobile phases, lamivudine and zidovudine are eluted at
similar retention times. In fact, they overlap in all mobile phases
except in 0.15 M SDS and 0.05 M SDS/1-propanol 2.5% where
an adequate separation is observed. Finally, 0.05 M SDS/1-
propanol 2.5% was selected as it provides a lower retention time
and maximum separation between the analytes.
Efavirenz was analyzed using other mobile phase. Among
those indicated in Section 3.1.1, 0.05 M SDS/1-pentanol 6% was
considered as optimal because it shows the maximal efficiency
(N ¼ 2569) and asymmetry (B/A ¼ 1.062).4332 | Analyst, 2012, 137, 4327–43343.1.3 Mixture 2: lamivudine + stavudine + efavirenz. Lam-
ivudine and stavudine show a similar behaviour in the studied
mobile phases; in fact, they are resolved only in aqueous mobile
phases and they co-elute when an organic modifier is added. The
mobile phase 0.05 M SDS was considered as optimal as it
provides the maximal separation between the two analytes,
maintaining a low retention time (less than 5 min). For efavirenz,
the same mobile phase as selected in Section 3.1.1 was taken.
3.1.4 Mixture 3: lamivudine + tenofovir + efavirenz. Teno-
fovir cannot be eluted using aqueous mobile phases, as it shows
too high a retention time. Lamivudine and tenofovir can be
analyzed together only in 0.05 M/1-propanol 2.5%. However, the
retention time was found to be high (z12.46 min) and the effi-
ciency was N ¼ 1889. Finally, tenofovir was analyzed using the
optimal mobile phase deduced in Sections 3.1.1 and 3.1.2 for
efavirenz (0.05 M SDS/1-pentanol 6%), were it provides a more
useful retention time (z4.01 min) and higher efficiency (N ¼
2060). Then this mobile phase was taken as optimal for the
quantification of tenofovir and efavirenz.
In this case, lamivudine was identified under other chro-
matographic conditions. The selected mobile phase was aqueous
0.15 M SDS without organic modifier, providing the elution of
the analyte at a low time (z2.69 min) but with enough separa-
tion from the dead time and with adequate efficiency (N¼ 2009).
3.1.5 Separation of standard and matrix compounds. Blank
serum samples (free of antiretrovirals) were studied in order to
assess if the analytes overlap with other compounds of the
matrix. In order to ensure that the tested blank serum samples do
not contain any antiretroviral, these samples were taken from ten
healthy volunteers (five males and five females) who have never
taken any of the studied drugs. Results (not shown) were found
to be similar for all the blanks. Despite the complexity of the
serum matrices, no peaks were detected with a retention time of
>2.00 min, but the front of the chromatograms showed a very
high absorbance. This can be explained by the use of micellar
media. Serum hydrophobic compounds are solubilized by their
introduction into the micelles (hydrophobic environment). When
the blank serum/micellar dilution sample is injected into the
chromatographic system, these interactions remain in the
micellar mobile phase, strongly decreasing the interaction
between these compounds and the stationary phase, and then
shortening the elution time. These results have already been
found in previous studies on the analysis of serum samples using
micellar mobile phases.13–15 Therefore, there are no compounds
that could overlap with the studied antiretrovirals because their
retention times were higher than 2.00 min, far enough from the
front of the chromatogram. Then in the spiked samples, the
chromatographic peaks corresponding to the antiretrovirals may
be observed as sufficiently separated between them and the other
peaks, thus avoiding overlapping. This proves the selectivity of
the method.3.2 Method validation
Validation was carried out following the guidelines of the FDA.19
The evaluated parameters were: linearity, limits of detection
(LOD) and quantification (LOQ), precision, accuracy andThis journal is ª The Royal Society of Chemistry 2012
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View Article Onlinerobustness. As lamivudine is resolved using three different
separation conditions depending on the HAARTmixture, and its
validation was performed for each mobile phase. The whole
calibration was performed using a spiked sample serum (initially
free of antiretroviral) from a healthy volunteer. In all cases, the
preparation of the spiked serum samples has been performed as
explained in Section 2.4.
3.2.1 Linearity and sensitivity. For calibration purposes, a
blank serum sample was spiked at nine concentration levels
between 0.5 and 50 ppm. The calibration was performed sepa-
rately for each antiretroviral.
The slope, intercept and regression level (r2) of the calibration
curves were obtained by linear correlation between the areas of
the chromatographic peaks of each analyte vs. the concentration
by unweighted least-square linear regression. Each calibration
level was repeated six times. Calibration was repeated five times
(preparing the samples on each occasion) on different days over a
period of two months. The regression curve of each analyte,
taken as the average of the five measurements is shown in
Table 2. The considered absorbance was in arbitrary units and
concentration was in ppm.
The LOD is defined as the lowest concentration in the serum
which provides a significant signal above the noise of the signal.
It is taken as 3 times the standard deviation of the blank (LOD,
3s criterion). The LOQ is defined as the lower amount of anti-
retroviral which can be reliably quantified and is set as the lower
concentration reached in the calibration curve.19 The LOD value
calculated for each analyte is shown in Table 2. The LOQ was
0.5 ppm for the studied antiretroviral.
3.2.3 Precision and accuracy. The intra- and inter-day
precision and accuracy of the proposed methodology were
calculated for each antiretroviral and HAART set. These
parameters were determined at 0.5, 5 and 20 ppm using spiked
serum samples.
The precision was determined as the standard deviation of the
provided signal (RSD, %), whereas the accuracy was calculated
as the recovery, i.e. the ratio between the detected and added
concentration. The intra-day analysis was determined by inject-
ing aliquots of these samples six times on the same day, while the
inter-day analyses correspond to the average of five measure-
ments of the intra-day values taken over a two-month period.
The results are shown in Table 3. For the quantification of the
five studied antiretrovirals, intra- and inter-day precision were
<7.1% and <5.2%, respectively, whereas intra- and inter-day
accuracy were between 88.5 and 105.3% and between 93.5 and
101.3%, respectively. These values are within the limits proposed
by the FDA guidelines, which accepts a maximal RSD of 15% for
precision and a recovery of between 80 and 120%.19
3.2.4 Robustness. The robustness of the method was per-
formed by analyzing serum samples (n ¼ 3) spiked with 20 ppm
of each studied antiretroviral, by making slight changes to the
following chromatographic conditions (with the others remain-
ing constant each time): SDS amount, quantity of organic
modifier, pH and flow rate. The variation of retention time and
peak area were studied. The robustness was examined for each
antiretroviral and each optimized mobile phase. InsignificantThis journal is ª The Royal Society of Chemistry 2012differences in peak areas and less variability in retention time
were observed (see Table 4). Results indicate that the selected
factors remain unaffected by small variations in these parame-
ters; the RSD was below 6.5%.
3.3 Analysis of real samples
The proposed method was applied to determine the levels of
antiretrovirals in serum samples from several AIDS patients
from a local Hospital. Only one kind of HAART regime has been
prescribed to each patient. For confidentiality reasons, no more
information about this can be provided. Results have been
organized depending on the set of antiretrovirals they take, as
can be seen in Table 5. Results have been shown considering the
1/10-dilution performed in the experimental procedure (Section
2.4). In the case of the measured amount of an antiretroviral
upper to 50 ppm, an extra 1/10-dilution was carried out. Fig. 2
shows the chromatogram of a patient to whom the mixture 1
HAART (lamivudine, zidovudine and efavirenz) has been
prescribed. Antiretrovirals were detected and quantified without
interferences. According to the results, the patient effectively
takes the medication.
4. Conclusions
Micellar liquid chromatography has been proven as a valuable
technique to monitor sets of antiretroviral drugs belonging to the
three HAART regimes mainly prescribed by doctors for AIDS
patients. Analysis was performed without long and tedious
extractions and/or sample cleaning, by the direct injection of the
sample after a simple dilution and filtration of the matrix. The
suggested methodology allows the separation of the analytes in
less than 15 min, with adequate efficiency and asymmetry.
Moreover, validation was performed according to FDA guide-
lines with satisfactory results in selectivity, linearity, sensitivity,
precision, accuracy and robustness. As low amount of organic
solvent and biodegradable salts were used, and the method can
be considered as environmentally friendly. Besides, the instru-
mentation is relatively inexpensive and a high amount of samples
can be successively analyzed using an autosampler, making it
more attractive in routine analysis for a hospital laboratory.
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